Klaria Pharma
Klaria Year-End Report 2023
Fourth quarter of 2023
Remaining business operations
- Net sales 0.0 MSEK (2.2 MSEK)
- Other income 0.2 MSEK (0.2 MSEK)
- R&D costs for the quarter amounted to 1.5 MSEK (8.6 MSEK)
- Profit after tax amounted to -7.9 MSEK (-12.9 MSEK)
- Earnings per share for the quarter amounted to -0.07 SEK (-0.22 SEK)
- Cash flow from operating activities amounted to -13.3 MSEK (-10.7 MSEK)
Business operations for sale
- Profit after tax amounted to -1.6 MSEK
The period January–December 2023
Remaining business operations
- Net sales 0.0 MSEK (5.9 MSEK)
- Other income 0.2 MSEK (0.7 MSEK)
- R&D costs for the period amounted to 4.5 MSEK (51.4 MSEK)
- Profit after tax amounted to -18.4 MSEK (-63.8 MSEK)
- Earnings per share for the period amounted to -0.18 SEK (-1.10 SEK)
- Cash flow from operating activities amounted to -15.4 MSEK (-49.8 MSEK)
Business operations for sale
- Profit after tax amounted to -17.4 MSEK
- Earnings per share for the quarter amounted to -0.17 SEK
| Datum | 2024-02-29, kl 16:30 |
| Källa | Cision |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.